InsidersTradesSigma
Total declarations
Company
▲ Purchases (13 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
13
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the complete record of transactions filed by FINE N SCOTT, Chairman & CEO. Insider active across 1 company, notably Cyclo Therapeutics, Inc.. Cumulatively, 14 reports have been recorded. Split: 13 buys · 0 sell. Total volume traded: €471k. History available since 15 September 2021. The latest transaction was disclosed on 20 October 2023 (X). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations14 total
299,402 shares@ US$0.7129.9% of flowCommon StockSEC:0001437749-23-028700:0
299,402 shares@ US$0.7128.9% of flowCommon StockSEC:0001437749-23-010877:0
Ideal exit: 15 Jan 2024 (T+270)
10,334 shares@ US$3.5811.7% of flowCommon StockSEC:0001437749-22-002613:0
Ideal exit: 4 Nov 2022 (T+270)
10,334 shares@ US$3.584.8% of flowCommon StockSEC:0001437749-22-002613
Ideal exit: 4 Nov 2022 (T+270)
5,000 shares@ US$3.896.2% of flowCommon StockSEC:0001437749-22-001188:0
Ideal exit: 16 Oct 2022 (T+270)
5,000 shares@ US$3.892.6% of flowCommon StockSEC:0001437749-22-001188
Ideal exit: 16 Oct 2022 (T+270)
5,000 shares@ US$3.892.6% of flowCommon StockSEC:0001437749-21-028622
Ideal exit: 11 Sept 2022 (T+270)
5,000 shares@ US$3.896.2% of flowCommon StockSEC:0001437749-21-028622:0
Ideal exit: 11 Sept 2022 (T+270)
5,000 shares@ US$4.937.9% of flowCommon StockSEC:0001437749-21-027709:0
Ideal exit: 29 Aug 2022 (T+270)
5,000 shares@ US$4.933.2% of flowCommon StockSEC:0001437749-21-027709
Ideal exit: 29 Aug 2022 (T+270)
5,000 shares@ US$5.253.4% of flowCommon StockSEC:0001437749-21-027140
Ideal exit: 16 Aug 2022 (T+270)
5,000 shares@ US$5.258.3% of flowCommon StockSEC:0001437749-21-027140:0
Ideal exit: 16 Aug 2022 (T+270)
5,000 shares@ US$6.359.7% of flowCommon StockSEC:0001437749-21-022183:0
Ideal exit: 12 Jun 2022 (T+270)
5,000 shares@ US$6.354.0% of flowCommon StockSEC:0001437749-21-022183
Ideal exit: 12 Jun 2022 (T+270)
14 of 14 declarations
About FINE N SCOTT
Scott N. Fine serves as the Chief Executive Officer of Cyclo Therapeutics, Inc. In this role, he leads the strategic operations of the company, which specializes in developing treatments for rare diseases. Scott is responsible for the overall vision of the company and the implementation of its business objectives. His leadership is essential in positioning Cyclo Therapeutics as a key player in the biotechnology sector.
